Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Therapeutics, Vertex Pharmaceuticals Ink $105M Collaboration Deal

NEW YORK (GenomeWeb) – CRISPR Therapeutics and Vertex Pharmaceuticals have linked up for a four-year strategic research collaboration to develop new treatments of genetic diseases using CRISPR/Cas9 genome editing.

The partners will evaluate the use of CRISPR/Cas9 in multiple diseases where gene targets have already been established by genetics research, including cystic fibrosis and sickle cell disease. Under the terms of the agreement, the partners will also evaluate an enumerated but undisclosed number of targets. Vertex will provide CRISPR Therapeutics with a $75 million up-front cash payment as well as a $30 million equity investment. CRISPR Therapeutics is also eligible to receive development, regulatory, and sales milestone payments of up to $420 million as well as royalty payments on future sales.

CRISPR Therapeutics will conduct the research, with Vertex covering all related expenses. Vertex holds the option to exclusively license up to six of any gene-based therapies that emerge from the collaboration.

The firms said in a statement that the initial focus of the collaboration will be to try to correct mutations in the cystic fibrosis transmembrane conductance regulator gene.

The collaboration will also focus on treatments for hemoglobinopathies, such as sickle cell disease. For treatments of these diseases, the partners will share all R&D costs equally and CRISPR Therapeutics will lead commercialization activities in the US.

The collaboration also provides Vertex with an observer seat on the CRISPR Therapeutics board of directors.

Basel, Switzerland-based CRISPR Therapeutics was co-founded by CRISPR/Cas9 pioneer Emmanuelle Charpentier and Nobel laureate Craig Mello, among others. The firm has R&D operations based in Cambridge, Massachusetts and corporate offices in London.

In May 2014, CRISPR Therapeutics raised $25 million in Series A funding.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.